Q2 Earnings Forecast for ITOS Issued By Leerink Partnrs

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Leerink Partnrs analyst D. Graybosch expects that the company will post earnings of ($0.62) per share for the quarter. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for iTeos Therapeutics' Q3 2025 earnings at ($0.48) EPS, FY2026 earnings at ($1.19) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at ($1.94) EPS.

Several other equities analysts have also weighed in on the company. Piper Sandler reaffirmed an "overweight" rating and issued a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday. Leerink Partners reaffirmed a "market perform" rating and issued a $9.00 price objective (down from $47.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Wedbush reaffirmed an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $13.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday. Finally, JPMorgan Chase & Co. lowered iTeos Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $15.00 to $8.00 in a research note on Tuesday, May 13th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $17.86.

iTeos Therapeutics Price Performance

ITOS opened at $7.81 on Monday. The stock has a market capitalization of $298.92 million, a price-to-earnings ratio of -2.48 and a beta of 1.39. iTeos Therapeutics has a 12 month low of $4.80 and a 12 month high of $18.70. The business has a 50-day moving average of $6.61 and a two-hundred day moving average of $7.40.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.14.

Institutional Investors Weigh In On iTeos Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in iTeos Therapeutics during the 4th quarter worth approximately $42,000. CWM LLC increased its holdings in shares of iTeos Therapeutics by 428.7% in the 1st quarter. CWM LLC now owns 8,554 shares of the company's stock valued at $51,000 after acquiring an additional 6,936 shares during the last quarter. Paloma Partners Management Co bought a new stake in shares of iTeos Therapeutics in the 1st quarter valued at approximately $65,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of iTeos Therapeutics in the 1st quarter valued at approximately $67,000. Finally, Virtus ETF Advisers LLC increased its holdings in shares of iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after acquiring an additional 3,293 shares during the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other iTeos Therapeutics news, major shareholder Ansbert Gadicke sold 1,031,931 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the sale, the insider now directly owns 3,452,797 shares in the company, valued at $27,829,543.82. The trade was a 23.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $5,079,339.46. Following the sale, the insider now owns 2,108,594 shares in the company, valued at $16,995,267.64. This represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 12.50% of the stock is owned by company insiders.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.